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The detection and characterization of antigen-specific T cell populations is critical for understanding the development
and physiology of the immune system and its responses in health and disease. We have developed and tested a
method that uses arrays of peptide–MHC complexes for the rapid identification, isolation, activation, and
characterization of multiple antigen-specific populations of T cells. CD4
þ or CD8
þ lymphocytes can be captured in
accordance with their ligand specificity using an array of peptide–MHC complexes printed on a film-coated glass
surface. We have characterized the specificity and sensitivity of a peptide–MHC array using labeled lymphocytes from T
cell receptor transgenic mice. In addition, we were able to use the array to detect a rare population of antigen-specific
T cells following vaccination of a normal mouse. This approach should be useful for epitope discovery, as well as for
characterization and analysis of multiple epitope-specific T cell populations during immune responses associated with
viral and bacterial infection, cancer, autoimmunity, and vaccination.
Introduction
Antigen-speciﬁc cellular immune responses are mediated
by a diverse population of T cells, each capable of recognizing
a speciﬁc peptide bound to a particular major histocompat-
ibility complex (MHC) molecule on the surface of host cells.
Recognition of peptides bound to class I or class II MHC
molecules leads to the clonal expansion, activation, and
maturation of T lymphocytes, resulting in effector popula-
tions of either cytotoxic (CD8
þ CTL) or helper (CD4
þ) T cells,
respectively. The presence of antigen-speciﬁc effector cells is
diagnostic of an immune response speciﬁc to that antigen;
detection of these antigen-speciﬁc cells is therefore critical
for the characterization of the response and for under-
standing its natural course. In addition, a systematic survey of
the global repertoire of T cell speciﬁcities, its dynamics over
time and between individuals, could be of great value in
elucidating the inner workings of the immune system and for
designing efﬁcient strategies for immunization, immunother-
apy, and treatment of autoimmune disease.
The development of peptide–MHC tetramers (Altman et al.
1996) and dimers (Greten et al. 1998) has allowed visualization
of antigen-speciﬁc T cells by ﬂow cytometry and, more
recently, in situ (Haanen et al. 2000) approaches. This has led
to characterization of T cell responses to speciﬁc antigens
associated with microbial pathogens (Callan et al. 1998; Ogg
et al. 1998a; Smith et al. 2000), autoimmunity (Ogg et al.
1998b), allergens (Seneviratne et al. 2002), and cancer cells
(Lee et al. 1999; Molldrem et al. 2000). Unfortunately, while a
signiﬁcant improvement over previous approaches, the use of
multimeric soluble peptide–MHC constructs in ﬂow cytom-
etry is technically difﬁcult, time consuming, expensive, and,
most importantly, limited to only one or a very few antigen
speciﬁcities at a time. cDNA-based expression libraries and
various forms of combinatorial synthetic peptide libraries,
such as the positional scanning combinatorial library (Pinilla
et al., 1994; Ignatowicz et al. 1996) and bead-bound libraries
(Hiemstra et al. 1997, 1998a, 1998b), have also been utilized in
attempts to study T cell receptor (TCR) speciﬁcity and
reactivity. However, these approaches have been hampered
by the intrinsic limitations of indirect readouts, such as
proliferation assays, and by the complexity of the libraries,
which do not allow for the direct visualization of T cell
interactions with diverse, but individually distinguishable,
antigens presented by an MHC complex. Consequently, the
various peptide library approaches are mainly effective when
used in combination with relatively homogeneous T cell
populations, such as T cell clones.
Here we report the development of a cellular array-based
screening strategy using microarrays of immobilized peptide–
MHC complexes. This approach is very rapid and allows the
simultaneous identiﬁcation, isolation, characterization, and
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PLoS BIOLOGYactivation of multiple antigen-speciﬁc populations of T cells.
Antigen-speciﬁc cells are captured onto an array of individ-
ual spots of peptide–MHC complexes, with cell capture at
each spot being dependent on T cell speciﬁcity. We
investigated the speciﬁcity of binding and the limit of
detection achievable by this method, using differentially
labeled CD8
þ and CD4
þ T cells of deﬁned speciﬁcity from
transgenic mice. We also found that T cell activation, upon
binding to the appropriate peptide–MHC on the array, could
be detected by visualizing a transient increase in intracellular
calcium. Finally, we have applied this method to detect a
weak, speciﬁc immune response in a normal mouse following
subcutaneous vaccination with ovalbumin (OVA). The sensi-
tivity and speciﬁcity of this approach, together with the
ability to survey a large number of speciﬁcities quickly and
easily, may provide a practical way to detect and screen for
natural immune responses and to characterize variations in
the T cell repertoire in healthy individuals and in a wide
variety of disease states.
Results
Construction of a Peptide–MHC Array
Detection of antigen-speciﬁc T cells using arrays of
peptide–MHC complexes was tested. We prepared phycoer-
ythrin (PE)-labeled peptide–MHC tetramers with the MHC
class I (H-2k
b) murine antigen OVA and MHC class II (I-E
k)
murine antigen moth cytochrome C (MCC), as described
(Altman et al. 1996). Both tetramers were validated by
ﬂuorescence-activated cell sorting (FACS) analysis using
OVA-speciﬁc T cells isolated from OT-1 TCR transgenic
mice (Hogquist et al. 1994) and MCC-speciﬁc 5c.c7 TCR
transgenic mice (Fazekas de St. Groth et al. 1993), respec-
tively. To facilitate a comparison between peptide–MHC-
mediated and antibody-mediated binding, the OVA and MCC
tetramers were arrayed along with antibodies against several
mouse lymphocyte cell surface antigens. Hence, individual
MHC tetramers and several monoclonal antibodies (mAbs)
were prepared in a 384-well plate at various concentrations
and dispensed in triplicate onto polyacrylamide ﬁlm-coated
glass slides. The latter were determined to be inert for cell
binding while having a high capacity for protein deposition
with relatively high ﬁdelity, as compared with a derivatized
glass slide (aldehyde-, Poly-L-Lysine-, and nitrocellulose-
coated slides were tested).
MHC tetramers and antibodies were arrayed using a piezo-
electric noncontact arrayer, which minimizes ﬁlm disruption
and allows control over spot size and the quantity of material
deposited, by enabling multiple nanoliter-scale drops to be
deposited onto each spot. The resulting spot size with ten 0.45
nl drops (dispensed at a concentration of 1lg/ll) was
approximately 400 lm in diameter. Each spot of this size
could accommodate approximately 1,600 closely packed T
cells. Suspended cells were subsequently layered onto the
array and were allowed to interact with the predispensed
tetramers and antibodies (Figure 1A). Following a short
period of incubation, the slide was washed to remove
unbound cells and visualized by direct inspection, differential
interference contrast (DIC), or ﬂuorescence microscopy.
Inspection by eye revealed tight, nearly conﬂuent cell clusters
on both the antibody and the MHC tetramer spots (Figure
1B).
To optimize the conditions for speciﬁc cell capture, we
investigated the relationship between the surface density of
the peptide–MHC complexes and the number of bound cells
(a detailed example is described in Supporting Information;
see, as part of this example, Figure S1). For a sufﬁciently
dense tetramer concentration, we found that the binding of
OT-1 cells to spots of OVA/K
b tetramer (OVA peptide 258–
265, H-2K
b class I MHC molecule, b2-microglobulin) or 5c.c7
cells to MCC/E
k tetramer (MCC peptide 88–103, I-E
k class II
MHC molecule, b2-microglobulin) was as efﬁcient as the
binding to spots of mAbs speciﬁc to cell surface markers, and
for a sufﬁciently dense cell suspension, conﬂuent cell binding
to the OVA/K
b tetramer could be achieved with 0.4–0.8 ng of
OVA/K
b tetramer per spot (corresponding to a spotting
solution concentration of 0.1–0.2 mg/ml).
Identification and Isolation of Antigen-Specific Cytotoxic
(CD8
þ) and Helper (CD4
þ) T Cells
We tested the speciﬁcity of binding to individual spots by
using pure populations of differentially labeled, antigen-
speciﬁc CTLs and helper T cells from transgenic mice.
Antigen-speciﬁc lymphocytes from OT-1 and 5c.c7 transgenic
mice were activated and expanded by adding 1 lM OVA and
MCC peptides to the respective single-cell suspensions on day
0, and IL-2 (30 U/ml) was supplemented on day 1. On day 7,
active OT-1 (CD8
þ) and 5c.c7 (CD4
þ) lymphocytes were
labeled with DiO or DiD–lipophilic tracers, respectively.
The two differentially labeled lymphocyte suspensions were
mixed in a 1:1 ratio and coincubated on the peptide–MHC
array. Following a 10-min incubation at 208C, the array was
washed twice in RPMI medium and examined by ﬂuorescence
microscopy (Figure 2). While anti-CD3 and anti-CD28 mAb
spots captured both lymphocyte populations, the arrayed
MCC/E
k and OVA/K
b tetramers exclusively captured the
MCC-speciﬁc (red) and OVA-speciﬁc (green) cells, respec-
tively. The nearly complete segregation of OT-1 and 5c.c7
cells on the appropriate spots illustrates the highly speciﬁc
nature of lymphocyte capture and the feasibility of array-
based T cell sorting and analysis.
Detection of Antigen-Specific T Cells in Complex Cell
Populations Using a Peptide–MHC Array
To directly assess the feasibility of detecting rare T cell
speciﬁcities in a complex population, we prepared synthetic
mixtures of differentially labeled, antigen-speciﬁc CTLs and
T helper cells, diluted with syngeneic wild-type lymph node
cells (Figure 3A) or splenocytes (Figure 3B). DiD-labeled OT-1
cells were diluted 1:100 (Figure 3A, top panels) and 1:1,000
(bottom panels) in DiO-labeled C57BL/6 mouse lymph node
cells that had been depleted of monocytes using anti-CD11b
beads (to remove cells capable of peptide-independent
binding to the MHC complex). OT-1 cells of 2.7310
4 (Figure
3A, top panels) and 4.41 3 10
3 (Figure 3A, bottom panels)
were mixed with 2.7 3 10
6 and 4.41 3 10
6 of CD11b-depleted
lymph node cells, respectively. The two different mixtures
were then separately incubated with identical peptide–MHC
arrays, each printed with OVA/K
b tetramer, LCMV/K
d control
tetramer (lymphocytic choriomengingitis virus gp peptide
33–41, H-2K
d class I MHC molecule, b2-microglobulin), MCC/
E
k tetramer, and three different antibody spots ( mouse anti-
CD8, mouse anti-CD4, and mouse anti-CD28). Following a
10–30 min incubation at 208Co r3 7 8C (similar results were
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Cellular Peptide–MHC Microarraysobtained), the cells were washed twice in RPMI and the slide
was scanned.
As expected, the resulting differential binding pattern was
primarily dictated by antigen speciﬁcity even in the presence
of a very large excess of nonspeciﬁc cells in the suspension. In
particular, the preferential binding of a sufﬁcient number of
OT-1 cells to the OVA tetramer (on both top and bottom
panels in Figure 3A), together with the absence of OT-1
binding to the LCMV tetramer, demonstrates the feasibility
of detecting as few as 0.1% of antigen-speciﬁc T cells.
Increasing the total cell number (10-fold increase is easily
achieved) and using CD8
þ instead of CD11b
  selection should
lead to further improvement in sensitivity (data not shown).
To test our ability to detect rare T helper cells speciﬁc for a
selected peptide–class II MHC, DiD-labeled 5c.c7 MCC-
speciﬁc lymphocytes were diluted to 1% abundance in
syngeneic, DiO-labeled B10A splenocytes (Figure 3B) and
incubated at 378C for 10 min. Despite the low percentage of
5c.c7 lymphocytes in the mixture (as reﬂected by the binding
to the anti-CD28 spot in the bottom right panel of Figure 3B),
many cells were bound to the MCC/E
k spots and almost all of
them were indeed found to be 5c.c7 cells (Figure 3B, right). In
a control experiment on a duplicate array without the 5c.c7
cells, none of the splenocytes adhered to the MCC spots.
Taken together, these results show that both class I and II
peptide–MHC complexes can be used to detect rare T cell
speciﬁcities in a complex cell population.
Detection of a Rare OVA-Specific T Cell Population in
Vaccinated C57BL/6 Mice
An important potential application of this technology is in
systematically monitoring the T cell repertoire in vivo and its
response to immunization, infection, and other stimuli. We
tested the feasibility of detecting a weak immune response by
monitoring the response of C57BL/6 mice to vaccination with
OVA (Figure 4). CD8
þ lymphocytes (2 3 10
6 and 3.2 3 10
6)
from the OVA-vaccinated and mock-vaccinated mice, re-
spectively, were incubated separately with duplicate peptide–
MHC arrays (on the same slide) containing OVA/k
b tetramer,
LCMV/k
d (control) tetramer, and various antibodies. The
arrays were incubated at room temperature for 30 min and
then washed with RPMI to remove free-ﬂoating cells. The
cells were also analyzed by ﬂow cytometry after staining with
anti-CD8–ﬂuorescein isothiocyanate (FITC) mAb and OVA/k
b
Figure 1. A Cellular Microarray
(A) A schematic diagram illustrating T cell binding to its cognate peptide–MHC spot via peptide–MHC–TCR interactions (not drawn to scale).
(B) Cells immobilized on the cellular microarray are immediately visible to inspection. When cell coverage exceeds approximately 20%
conﬂuency, the cluster becomes visible to the naked eye. Shown are cell clusters bound to several triplicate spots of either peptide–MHC
complexes or antibodies. The image was taken using a digital camera. The arrows and legends indicate the locations and identities of each of the
printed triplicates. Spot diameter and interspot distance are about 400 lm and 700 lm, respectively. Scale bar is 1.4 mm in length.
DOI: 10.1371/journal/pbio.0000065.g001
Figure 2. Specificity of Lymphocyte Immobilization by Peptide–MHC
Arrays
Prelabeled, OVA-speciﬁc OT-1 (green) and MCC-speciﬁc 5c.c7 (red)
lymphocytes (6 310
5) were mixed at a 1:1 ratio and added to the
preprinted peptide–MHC array. While anti-CD3 and anti-CD28 mAb
spots (left and right top panels) immobilize both lymphocyte
populations, the OVA and MCC tetramers (left and right bottom
panels) capture only the OVA-speciﬁc and MCC-speciﬁc cells,
respectively. Cells were labeled with DiO and DiD lipophilic tracers
that incorporate into the cell membrane and do not affect the
speciﬁcity of cell capture. The printed peptide–MHC tetramer spots
contain the ﬂuorescent dye, which allows visualization of peptide–
MHC spot borders (data not shown).
DOI: 10.1371/journal/pbio.0000065.g002
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Cellular Peptide–MHC Microarraysstreptavidin (SA)–PE tetramer. FACS analysis revealed that a
small fraction (0.27%) of the CTLs from the vaccinated
mouse are OVA-speciﬁc, whereas the control mouse did not
exhibit an OVA-speciﬁc response (Figure 4B). A small but
signiﬁcant number of cells from the OVA-vaccinated mouse
were captured on the OVA/K
b spots, while none were bound
by the LCMV/K
d tetramer spot (Figure 4A). Cells from the
mock-vaccinated mouse did not bind to either of the
peptide–MHC tetramers. These results demonstrate that
these arrays can provide a way to detect even very weak
immune responses in normal mice. The ability to use this
approach to detect postvaccination populations of peptide-
speciﬁc T cells in wild-type immune responses has been
further conﬁrmed with different peptide–MHC systems
(unpublished data).
Specific Activation of Lymphocytes Bound to a Peptide–
MHC Array Spot
The ability to observe highly speciﬁc interactions between
live lymphocytes and arrays of proteins raises the possibility
of conducting systematic parallel studies of responses to
diverse signals arrayed on the surface. We therefore tested
the possibility of using a protein array to investigate dynamic
responses of lymphocytes to diverse signals, including speciﬁc
peptide–MHC complexes and other receptor-speciﬁc binding
molecules. OT-1 lymphocytes were loaded with the calcium-
sensitive dye Fura-2 and were subsequently exposed to an




anti-CD28, and anti-CD3/anti-CD28 spots. Throughout the
experiment, the array was kept at 378C and 5% CO2, and
intracellular calcium levels were monitored every 30 s by
measuring the ratio of the ﬂuorescence intensity at 340 nm
and 380 nm. Binding of OT-1 lymphocytes to the OVA/K
b,
anti-CD3, and anti-CD3/anti-CD28 MHC array spots, but not
to LCMV/K
d, MCC/E
k, or anti-CD28, led to transient spikes in
intracellular calcium levels (Figure 5).
Discussion
Cellular immune responses to pathogens, allergens, de-
regulated or mutated proteins, and self-antigens play critical
roles in health and disease. The ability of T cells to respond to
the immense diversity of possible targets relies on the
corresponding diversity of the repertoire of TCRs that can
Figure 3. Sensitivity of Peptide–MHC Tetramer-Mediated Detection of OVA-Specific CTLs and MCC-Specific Helper T Cells
(A) DiD-labeled OT-1 OVA-speciﬁc cells (red) were diluted 1:100 (top panels) or 1:1,000 (bottom panels) in DiO-labeled, monocyte-depleted
C57BL/6 mouse lymph node cells (green). DiD-labeled OT-1 cells of 2.7 3 10
4 (top panels) and 4.41 3 10
3 (bottom panels) were mixed,
respectively, with 2.7310
6 and 4.41310
6 of DiO-labeled CD11b-depleted lymph node cells. The different dilutions were applied to identical but
separate arrays printed with the OVA/K
b tetramer, the LCMV/K
d control tetramer, and three different antibody spots (mouse anti-CD8, mouse
anti-CD4, and mouse anti-CD28). Following 10-min incubation at 378C, the cells were washed in RPMI and the slide was scanned. Shown are the
OT-1 (red) and lymph node (green) cells that were captured by the OVA tetramer (left), LCMV tetramer (second left), and the antibody spots.
(B) Class II MHC-mediated detection and sorting of helper T cells. DiD-labeled 5c.c7 lymphocytes (3.5310
4) (red) were diluted 100-fold in 3.63
10
6 B10A DiO splenocytes (green). The mixed suspension was incubated at 378C for 10 min prior to wash with RPMI. Shown are the 5c.c7 sells
(red) and splenocytes (green) captured by the MCC (left) and anti-CD28 (right) spots.
DOI: 10.1371/journal/pbio.0000065.g003
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Cellular Peptide–MHC Microarraysbe generated by the immune system. The T cell population in
each individual is diverse and dynamic. Even after exposure
to a potent T cell antigen, an individual TCR clone seldom
accounts for more than 5% of the total population of T cells
in a normal human or mouse. Moreover, the speciﬁcities and
phenotypes of the individual’s T cell repertoire may provide a
rich picture of the immunological history, the physiological
status, and perhaps the disease susceptibilities of that
individual. A broad picture of the dynamic responses of the
T cell repertoire to an immunological challenge should
illuminate our understanding of the immune response and
may point to individual-speciﬁc response patterns that can
help guide design of immunological therapies.
The development of peptide–MHC tetramers (Altman et al.
1996) and variations (Greten et al. 1998) as staining reagents
has greatly aided the analysis of antigen-speciﬁc populations
of CD4 and CD8 T cells. Unfortunately, the number of
speciﬁcities that can be analyzed is severely limited by the
ﬂuorescence spectra available for conjugation to individual
peptide–MHC complexes.
Furthermore, the complex compensation required for
multiple ﬂuorophores and numerous controls required for
adequate tetramer staining, such as a control tetramer,
propidium iodide for dead cell staining, anti-CD8, anti-
CD11, anti-CD19, and anti-CD56, further restrict the ability
to analyze multiple speciﬁcities simultaneously. Hence,
analyzing more than a few speciﬁcities is difﬁcult and is
impractical for a typical clinical sample. By using speciﬁed,
predetermined spatial coordinates rather than ﬂuorescent
tags, microarray technology has revolutionized the analysis of
gene and protein expression, allowing the simultaneous
analysis of hundreds to thousands of different variations in
gene and protein expression. This approach has been
recently used to analyze intact cells (Belov et al. 2001; Brown
et al. 2003), allowing the simultaneous characterization of
hundreds of cell surface molecules, by applying a homoge-
nous population of cells to an array of mAbs. We have
extended the experimental logic of that approach to the
characterization and isolation of antigen-speciﬁc populations
of T cells from a heterogeneous cell mixture. Furthermore,
cospotting peptide–MHCs with other effector molecules and/
or co-culturing the T cells with other effector cells may allow
for high throughput examination of MHC presentation in the
context of other molecular signals and might open exciting
avenues for antigen-speciﬁc intercellular interaction assays.
Together, these methods should provide an efﬁcient ap-
proach to epitope discovery and broad, systematic character-
ization of TCR speciﬁcity and the relations between epitope
recognition and T cell activation, reactivity, anergy, and cell
death.
Figure 4. Detection of a Weak Immune
Response to Vaccination
CTLs from OVA-vaccinated and mock-
vaccinated mice were analyzed in paral-
lel using an MHC array and ﬂow cytom-
etry analysis. Mice received base-of-tail
injections of OVA/Freund’s adjuvant
emulsions or PBS (mock)/Freund’s adju-
vant on day 0 and day 7. Draining lymph
nodes were harvested on day 11, and
dissociated into a single-cell suspension.
(A) CTLs were enriched on an anti-CD8-
bead column. Cells (2 3 10
6 and 3.2 3
10
6) from the OVA- and mock-vacci-
nated mice, respectively, were incubated




trol) tetramer, and various antibodies.
The three panels show the relevant array
results. A rare population of cells from
the OVA-vaccinated mouse was captured
on the OVA/K
b (left), but not on the
LCMV/K
d (right), tetramer spot. The cells
captured on the OVA/K
b tetramer spot
were CD8
þ (as determined by counter-
staining using an anti-CD8–FITC mAb
on the array). An arrowhead points to
some of the cells that were bound to that
spot. The cells from the mock-vaccinated
mouse did not bind the OVA tetramer
(middle spot) or the LCMV/K
d tetramer
(data not shown). Spot regions are
marked with a blue color by overlaying
the tetramer’s PE ﬂuorescent signal onto
the DIC image.
(B) FACS analysis of the cells from the
OVA-vaccinated (left panel) and mock-
vaccinated mice (right). Of the total
CD8
þ cells from the vaccinated mouse,
0.27% co-stain with OVA/K
b, compared
with 0.01% in the mock-vaccinated
mouse.
DOI: 10.1371/journal/pbio.0000065.g004
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binding probes in our cellular microarray format is somewhat
surprising because the typical TCR afﬁnity is about 10
3-t o
10
4-fold lower than that of a typical mAb and its antigen
(Davis et al. 1998). Still, sufﬁcient numbers of peptide–MHC
complexes bound to a given cell can compensate for relatively
low afﬁnity of a single peptide–MHC–TCR interaction. In
fact, a simple order of magnitude calculation shows that for a
typical peptide–MHC concentration, as few as approximately
200 peptide–MHC–TCR interactions are sufﬁcient to capture
and stably hold a cell against typical ﬂow forces experienced
during the washing of unbound cells (an example of this
calculation is provided in the Supporting Information
section).
The combination of large spots on an inert substrate allows
the reliable detection of as few as three to ﬁve bound cells per
spot. For cells with a diameter of 10 lm on a 400 lm spot, this
corresponds to a dynamic range of about 300-fold, which can
be further increased using larger spot sizes (i.e., dispensing
more drops on each spot) or using multiple spots of the same
size. More importantly, since rare populations of cells can be
detected only when a sufﬁcient number of them encounter
the appropriate probe region, the total probe area (i.e.,
surface area of one spot multiplied by the number of
identical spots) has a major effect on the sensitivity. We have
shown that the limit of detection with a single 400 lm spot of
a weak model antigen is about 0.1% (i.e., one positive out of
1,000 cells). Increasing the number of identical spots results
in an improvement in sensitivity, the extent of which is under
investigation. Further improvement might be achieved by
increased exposure of cells to each MHC-printed region (e.g.,
by sample agitation, reloading, or directed ﬂow). Another
route towards a signiﬁcant improvement in both sensitivity
and signal-to-noise ratio is cell enrichment prior to MHC
array analysis. For example, preselection of CD8
þ or CD4
þ
from peripheral blood mononuclear cells (e.g., by bead
selection or FACS sorting) results in approximately a 10-fold
enrichment of speciﬁc target cells and eliminates the
nonspeciﬁc binding of a subpopulation of CD11b
þ cells to
MHC spots. Further enrichment via negative and/or positive
selection using common markers would almost certainly
extend the lower limit of partial abundance required for
detection.
The number of cells captured on the array depends on the
abundance of cells expressing the appropriate TCR, its
expression level, and afﬁnity to the peptide–MHC complex,
the concentration, functionality, and accessibility of that
complex, and several other factors, including the local cell
Figure 5. Activation of OT-1 Lymphocytes
Following an Exposure to Preprinted Spots
on an MHC Array
OT-1 lymphocytes were preloaded with
Fura-2 dye for 20 min at room temper-
ature prior to exposure to the cellular
microarray (time 0).T h ec e l l sw e r e
incubated at 378C, 5% CO2, and ﬂuo-
rescence intensities at 340 nm and 380
nm were measured every 30 s from each
of the spots on the array. Calcium ﬂux
signal was triggered in the OVA-speciﬁc
cells as soon as they reached the OVA/K
b
tetramer spots, the activating antibody
spots (anti-CD3 and anti-CD3/anti-
CD28), but not the irrelevant MCC/E
k
tetramer or the nonactivating antibody
spots (e.g. anti-CD28).
(A) Calcium ﬂux signal (yellow) overlaid
onto a 10x DIC image of OT-1 cells on a
combined FITC-labeled anti-CD3/anti-
CD28 spot. Fura-2 ﬂuorescence intensity
ratios are represented in pseudo-color,
and the overlaid spot region (blue) is
determined from the FITC image. Note
that the spot pattern can be inferred
from the Fura-2 signal representing
activation, even without removing un-
bound cells.
(B) A time-lapsed series of images taken
of a representative OT-1 lymphocyte
speciﬁcally immobilized onto an OVA/
K
b spot. The cell undergoes a rapid,
transient calcium ﬂux as measured by
Fura-2 ﬂuorescence.
(C) Averaged calcium ﬂux traces (n ¼ 3)
recorded from an OVA/K
b spot (purple
circles), anti-CD3/anti-CD28 spot (brown
triangles), anti-CD3 spot (green circles),
and nonactivating anti-CD28 spot (or-
ange triangles). Error bars represent
calculated standard error of mean.
DOI: 10.1371/journal/pbio.0000065.g005
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Cellular Peptide–MHC Microarraysdensity, incubation, and washing conditions, local ﬁlm,
integrity etc. Consequently, estimating the frequency of cells
expressing a given antigen speciﬁcity requires the develop-
ment of a standardized protocol. One possible approach is to
coexpose differentially labeled cell populations to the same
spots using a standard pool of T cells as a common internal
standard in each analysis, analogous to the reference RNA
commonly used for DNA microarray studies of gene
expression (Eisen and Brown 1999). The use of a common
internal standard can provide a way to eliminate local spot-
and slide-dependent factors and obtain a relative measure for
the number of cells that are above the threshold for
functional binding, allowing quantitative differential proﬁl-
ing of cell surface markers based on the relative number of
bound cells.
The use of printed arrays of speciﬁc binding reagents for
characterizing populations of cells has similarities to FACS in
concept and applications. FACS has the advantage of allowing
analysis on a cell-by-cell basis, while the cellular microarray
approach allows a much larger number of molecules to be
analyzed in a population of cells. Currently, a single cellular
microarray can accommodate more than 1,000 peptide–MHC
probes (without decreasing the spot size), which allows
detection of 1,000 antigen-speciﬁc cell populations in a
single assay. Each cellular microarray-based assay is easy to
perform, utilizes ﬁxed gating that eliminates the subjective
gating of FACS-based analysis, and allows many samples to be
analyzed side by side either on the same slide (for small
arrays) or on different slides. The high throughput should
make it practical to screen a sample population of cells (e.g.,
from a patient) against a large panel of candidate peptide–
MHC complexes or to discover novel MHC-restricted
epitopes by screening libraries of random, mutated, and
chemically modiﬁed sequences. Although the fractional
abundance of speciﬁc T cells required for detection in our
experiments (0.1%) is not as low as can be detected in the best
FACS analyses (0.01%), it is already sufﬁcient to identify an
immune response of clinical relevance and is likely to
improve with further optimization.
What are the prospects for efﬁcient array-based detection
of immune responses and characterization of the TCR
recognition and activation landscape? The actual set of
TCR speciﬁcities and sensitivities, at any given time, depends
on the history of exposure to antigens, genotype, and the
physiological parameters. We have shown that a physiologi-
cally relevant response to an antigen challenge is detectable
as cell capture by the cognate peptide–MHC (see Figure 4).
Since an expanded population of activated T cells may cross-
react with epitopes having a considerable degree of sequence
homology (Reay et al. 1994; Wucherpfennig and Strominger
1995; Kersh and Allen 1996; Bach et al. 1998; Honeyman et al.
1998; Mason 1998; Zhao et al. 1998; Hiemstra et al. 1999;
Misko et al. 1999), a signature of binding to multiple peptides
is also possible, especially for structurally similar epitopes
(high surface concentration of the peptide–MHC may further
contribute to the ability to capture cross-reacting T cells).
Moreover, in numerous important pathologies associated
with both speciﬁc and nonspeciﬁc polyclonal activation of
the host immune system, the binding of activated clones to
many unrelated (and often self-protein-derived) peptides is
very plausible. For example, a single cancer patient can
develop immune responses to multiple tumor-associated
antigens (Rosenberg 2001). In one case, tumor-inﬁltrating
lymphocytes from a single patient recognized tyrosinase (a
differentiation antigen presented by human leucocyte anti-
gen [HLA] class I), b-catenin (a class I mutation), p15 (a class I
antigen involved in posttranscriptional control), gp100 (a
class I intronic sequence and class II normal sequence),
tyrosinase-related protein-1 (TRP-1, a class II differentiation
antigen), TRP-2 (a class II differentiation antigen), and Ki-67
(a class II mutation).
The wide range of speciﬁcities against nonhomologous
antigens demonstrated in this and other reports strongly
supports the feasibility of cellular microarray-based charac-
terization of patient-speciﬁc immune response patterns. An
example for a nonspeciﬁc, clinically important response is a
superantigen-induced stimulation, which often leads to a
massive polyclonal lymphocyte activation that might account
for up to 30% of the host T cell repertoire (depending on the
number of Vb families capable of interacting with the
superantigen) (Muller-Alouf et al. 2001). Still, while the
cellular microarray should be sensitive enough to identify
and examine binding patterns in activated samples, its ability
to characterize the naive repertoire might be limited. This
drawback may be mitigated by modifying the geometry of the
array and/or the sample introduction method so as to
increase the chances of rare cell populations encountering
each of the peptide–MHC complexes.
Taking advantage of the full potential of this approach
requires convenient means for synthesizing diverse arrays of
peptide–MHC complexes. Conventional MHC tetramer syn-
thesis is cumbersome and technically difﬁcult, making the
effective implementation of large, functional peptide–MHC
libraries a practical challenge. However, usage of reloadable
MHC constructs such as DimerX (BD Biosciences) or the
MHC tetramer-based Epitope Discovery System (Beckman
Coulter) should allow for an efﬁcient production of printable
MHC molecules loaded with diverse peptide epitopes of
interest. Indeed, preliminary experiments suggest that the
DimerX peptide-loadable reagent has a similar speciﬁcity and
sensitivity to that of peptide–MHC tetramers.
The experimental strategy introduced here provides a
powerful tool for simultaneous detection and study of
antigen-speciﬁc T cell populations. This technique can be
performed rapidly (10 min), requires little technical exper-
tise, and allows screening of a single clinical sample (with
CD4
þ and/or CD8
þ T cells) against a library of speciﬁc or
random peptide–MHCs. Although the data presented here
were generated using cells derived from mice, preliminary
results indicate that this approach works equally well with
human samples. Numerous clinically signiﬁcant MHC-re-
stricted epitopes have already been deﬁned. These can be
easily printed on a single microarray to provide a rapid test
for the cognate T cell responses and to study the involvement
of multiple epitopes during the course of a disease or
following vaccination. Co-immobilization with effector mol-
ecules and cells may assist in identifying key factors that take
part in the regulation of T cell effector function. Thus, the
development of peptide–MHC cellular microarrays should
provide valuable insights into dynamic and individual
variations in the global repertoire of T cell speciﬁcities and
the mechanisms that control them.
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Peptides and cell lines. MCC 88–103 (ANERADLIAYLKQATK),
OVA 258–265 (SIINFEKL), HIV gag 77–85 (SLYNTVATL), and LCMV
gp1 33–41 (KAVYNFATC) peptides have been produced at the
Protein and Nucleic Acid Facility at Stanford University (Stanford,
California, United States).
OT-1 TCR transgenic mice (Hogquist et al. 1994) bred into a wild-
type C57BL/6 background (Fazekas de St. Groth et al. 1993),
expressing homozygous for MHC class I-restricted OVA-speciﬁc
TCR, were a generous gift from Dr. Stephen Schoenberger (San
Diego, California, United States). 5c.c7 areTCR transgenic mice
expressing homozygous for MHC class II MCC-speciﬁc TCR. Animals
were housed in a pathogen-free condition.
Peptide–MHC class I tetramer preparation and staining. This
technique was developed in the Davis lab (Altman et al. 1996) and has
been widely used. In brief, a 15 amino acid linker/BirA substrate
peptide (BSP) for BirA-dependent biotinylation has been genetically
engineered onto the COOH terminus of the mouse H-2K
b or I-E
k
gene. The MHC class I/BirA substrate peptide fusion protein was
expressed in Escherichia coli with b2-microglobulin and folded in vitro
with speciﬁc peptide ligands. The properly folded peptide–MHC class
I–b2-microglobulin complex was then extensively puriﬁed and
biotinylated on a lysine residue within the BSP using the BirA
enzyme (Avidity, Denver, Colorado, United States). Tetramers were
produced by adding to biotinylated peptide–MHC complexes PE–SA
(Prozyme, San Leandro, California, United States) at a molar ratio of
4:1. Speciﬁcity is demonstrated by lack of staining in irrelevant CTLs.
Tetramers were individually titrated and used at the optimum
concentration based on signal-to-noise ratio, usually 10 lg/ml. LCMV/
K
d was purchased from Beckman Coulter (Allendale, New Jersey,
United States). Cells (1310
6) were stained with the speciﬁc tetramer
of interest for 30 min at 48C. Antibodies were then added at the
recommended concentrations and incubated for 30 min at 48C.
Preparation of MHC and antibody arrays. The following MHC
tetramers and antibodies were prepared in a v-shaped 384-well plate
(Genetix Pharmaceuticals, Cambridge, Massachusetts, United States)
with approximately 12 ll per well: (i) a 2-fold dilution series of OVA/
H-2K
b tetramer (1 to 1:163, with 13concentration being 0.17 mg/ml),
(ii) gp100/HLA-A2 tetramer (at 0.52 mg/ml), (iii) MCC/I-E
k tetramer
(0.42 mg/ml), (iv) LCMV/H-2K
d tetramer (Beckman Coulter) at 0.33
mg/ml, (v) mouse anti-CD3 mAb (clone 17A2; BD Pharmingen, San
Diego, California, United States) at 0.5 mg/ml, (vi) mouse anti-CD28
mAb (clone 37.51; BD Pharmingen) at 0.5 mg/ml, and (vii) a 1:1
mixture of mouse anti-CD3 and mouse anti-CD28 (each at a ﬁnal
concentration of 0.25 mg/ml). Each of the tetramer and DimerX
solutions were supplemented with 2% glycerol. All samples were
arrayed in triplicates onto three-dimensional substrates comprised of
microscope slides coated with a polyacrylamide gel (Perkin Elmer,
Boston, Massachusetts, United States). Slides were processed for
printing according to the manufacturer’s instructions, and the
samples were then dispensed with a noncontact piezo-electric arrayer
(Perkin Elmer). About 4.5 nl of sample (10 drops of approximately
0.45 nl) were dispensed on each spot (approximately 400 lmi n
diameter). To allow for more than one independent assay on each
slide, each of the samples (or, in some cases, part of the samples) was
dispensed in two groups (or blocks) with an intergroup distance of 5
mm. Following the print run, the arrayed proteins were immobilized
within the gel substrate by incubating the slides for 24 h at 48Ci na
humid chamber. Following the immobilization, the arrays were
placed in a dry slide box, sealed with tape, and stored at 48C until
used. Stored slides were used for 5 mo without an observed reduction
in activity or diffusion of the spotted constructs (lack of diffusion was
determined by examining the diameter of the PE-labeled MHC
tetramer spots as viewed by ﬂuorescence microscopy).
Array panning. OT-1 and 5c.c7 transgenic mice were sacriﬁced on
day 0 by cervical dislocation. Axillary and inguinal lymph nodes were
harvested and a single-cell suspension obtained by straining through
a 70-lm cell strainer (BD Falcon, San Diego, California, United
States) in RPMI fortiﬁed with 10% fetal calf serum (FCS), penicillin,
streptomycin, glutamine, b-mercaptoethanol, and nonessential amino
acids. OVA or MCC peptide (1 lM) was then added and the cells were
incubated at 378C. On day 1, murine IL-2 (Sigma, St. Louis, Missouri,
United States) was added to the lymphocytes to a ﬁnal concentration
of 30 U/ml. On days 7–10, lymphocytes were suspended in RPMI
(deﬁcient in phenol red) with 5% FCS at a concentration of 10
4–10
8
cells/ml prior to incubation on the peptide–MHC tetramer array.
B10A or C57BL/6 mice were sacriﬁced, and single-cell splenocyte
suspensions was subjected to a Ficol gradient and CD11b
  depletion
(Miltenyi Biotec, Bergisch Gladbach, Germany) prior to being used as
syngeneic controls. Cells were labeled with ﬂuorescent lipophilic
tracers DiO, DiD, and DiI (Molecular Probes, Eugene, Oregon, United
States) according to the manufacturer’s instructions. Labeled or
unlabeled cells were directly added to the peptide–MHC array by
gentle layering in volumes of 20–50 ll. The array was incubated either
at 378Co r2 0 8C for 10–30 min. Following incubation, the array was
washed twice with RPMI to remove unbound cells. (For more detailed
information, see Protocol S1.)
Detection of a weak postvaccine immune response. MHC arrays
were used to monitor CD8-speciﬁc immune responses to OVA
vaccination in wild-type C57BL/6 mice. Mice received base-of-tail
injections of 1:1 OVA (100 lg in 100 ll of phosphate-buffered saline
[PBS]; Sigma)/Freund’s adjuvant (Sigma) emulsions or PBS/Freund’s
adjuvant (mock vaccination) on day 0 and day 7. Mice were sacriﬁced
on day 11 and underwent anti-CD8
þ selection (Miltenyi Biotec) from
single-cell suspensions derived from mouse lymph nodes. CD8
þ
lymphocytes from both OVA- and mock-vaccinated mice were
applied to separate MHC arrays. FACS analysis of the same
population of cells was performed as detailed above, with anti-
CD8–FITC mAb, OVA/K
b SA–PE tetramer, and an HIV gag 77–85/
HLA-A*0201 SA–PerCP dump tetramer. FACS analysis was per-
formed on a Becton Dickenson LSR at the Stanford University FACS
Facility (Stanford, California, United States).
Intracellular calcium measurements. To determine whether the
MHC array could be used to probe intact lymphocyte activation
pathways, OT-1 lymphocytes were loaded with 5 lg/ml calcium-
sensitive dye Fura-2 (Molecular Probes) for 20 min at room




k, anti-CD3, anti-CD28, and
anti-CD3/anti-CD28 spots. Intracellular calcium levels were moni-
tored every 30 s by measuring the ratio of the ﬂuorescence intensity
at 340 nm and 380 nm using the ﬂuorescence microscopy equipment
detailed below.
Array imaging. Imaging was performed using a Zeiss (Oberkochen,
Germany) Axiovert-100TV microscope and a Fluor 10x ﬁtted with a
high-speed piezo-electric z-motor (Physik Instruments, Downing-
town, Pennsylvania, United States), Princeton Instruments liquid-
cooled CCD Interline camera (Roper Scientiﬁc, Trenton, New Jersey,
United States), and dual excitation and emission ﬁlter wheels (Sutter
Instruments, Novato, California, United States). A DIC image, a Cy3
(for DiI or PE), a Cy5 (DiD) and/or a FITC (DiO) image, and/or 340 nm
and 380 nm images were collected every 30 s for up to 1 h.
Microscope control, acquisition of data, and image analysis were
performed using Metamorph (Universal Imaging, Downingtown,
Pennsylvania, United States).
Supporting Information
To evaluate the effect of tetramer dilution on cell capture, we
printed an OVA/k
b tetramer dilution series and probed it with OT-1
cells (Figure S1A). The cells were suspended at 2.5 310
6 cell/ml (10
5
cells in 40 ll), which was below the concentration required for
conﬂuent coverage of the spot area. The cells were then incubated
with the array (30 min at room temperature) and imaged following
washout of unbound cells. In this speciﬁc example, the number of
cells captured increased linearly with the amount of tetramer
deposited (Figure S1B), with a binding threshold of approximately
0.05 ng/spot. The lack of plateau at high tetramer concentrations,
together with the denser cell coverage on the anti-CD3 spots, suggests
that a still further increase in tetramer concentration (without
changing the suspension density) would result in higher numbers of
bound cells. Indeed, a 4-fold increase in the amount of tetramer
deposited leads to a signiﬁcant increase in binding efﬁciency, which
becomes comparable to binding via a mAb (data not shown). The lack
of cell binding between spots or to noncognate peptide–MHC spots
indicates that binding of as low as a few cells is attributable to
peptide–MHC–TCR recognition. Note, however, that the linear shape
of the binding curve (Figure S1B) should be considered as a special
case and not as a general rule. Likewise, the minimal concentration
for binding depends on the availability and functionality of the
immobilized peptide–MHC, the peptide–MHC–TCR afﬁnity, the
type, density, and heterogeneity of the cells, the incubation temper-
ature and duration, and the stringency of washing.
In general, the binding curve should depend on the immobilization
kinetics, the heterogeneity in TCR expression level, and its afﬁnity to
the peptide–MHC complex. For a sufﬁciently dense, homogeneous
cell suspension, we expect to ﬁnd a sigmoidal binding curve with a
sharp transition from no binding to a plateau at some critical
tetramer concentration. Indeed, in some other peptide–MHC–TCR
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sigmoidal shape (data not shown). Heterogeneity in TCR afﬁnity and
expression level should lead to a less steep increase in captured cell
number as a function of surface ligand density. Therefore, the linear
binding curve (Figure S1B) probably reﬂects a wide distribution of
TCR expression levels and/or afﬁnities and should not be considered
as a pure statement on binding kinetics. Still, an exact linear curve is
somewhat surprising.
The excellent performance of peptide–MHC complexes as binding
probes in an array format was somewhat surprising because the
typical TCR afﬁnity is about 10
3-t o1 0
4-fold lower than that of a
typical mAb and its antigen (Davis et al. 1998). Still, sufﬁcient
numbers of peptide–MHC complexes bound to a given cell can
compensate for relatively low afﬁnity of a single peptide–MHC–TCR
bond. By incorporating kinetic parameters speciﬁc to the OT-1/OVA
tetramer interaction into a simpliﬁed adhesion model proposed by
Bell (1978), the actual number of OT-1/OVA/K
b tetramer bonds can
be estimated as follows. Each spot typically contains approximately 2
310
10 tetramers, corresponding to a maximal surface concentration
of about 1.5 3 10
13/cm
2. Since the tetramers are deposited into a
three-dimensional ﬁlm, and some of them may lose their function-
ality during the deposition and thereafter, the actual surface
concentration may be signiﬁcantly smaller. Assuming that only about
1% of the tetramers are actually available for binding, the critical
force per bond, above which a cell cannot be stably bound to the
surface (Bell 1978), is given by fc ’ 6310
 123Ln (Ns/KD
(2d)) ’ 35pN/
bond, where Ns is the effective surface concentration of the tetramer
and KD
(2d) is the estimated two-dimensional dissociation constant





For medium viscosity g¼7310
 3 g/(cm/s) and cell radius a¼3 lm,
the hydrodynamic Stocks force, F, exerted by a constant ﬂow during
washout of unbound cells is given by F¼6pgat, where t is the velocity
of the slide as it moves through the washing medium. Hence, for a
typical washing velocity of 10 cm/s, the detaching force F ¼ 4nN may
be compensated by as few as 114 OT-1/OVA tetramer bonds.
Assuming an interaction area of 15 lm
2, the surface concentration
of bound OT-1 TCRs at the time of washing must be higher than 7.6/
lm
2. Such surface density can be easily achieved even for a uniform
TCR surface distribution. For example, for a T cell of radius a, having
a uniform TCR distribution, a surface density of 7.6/lm
2 corresponds
to a total of 382 TCRs. In a typical OT-1 cell, the TCR expression level
is about two orders of magnitude higher than this lower bound. A
more realistic scenario of TCR recruitment to the ‘‘artiﬁcial
immunological synapse’’ (resulting in a nonuniform TCR distribu-
tion) would correspond to an even lower bound.
Thus, given the relevant physiological and kinetic parameters
(incorporated into a simpliﬁed adhesion model), the major determi-
nant of cell capture is the surface density, Ns, of functional peptide–
MHC complexes. For a sufﬁciently high Ns, the critical force per
bond, fc, is high enough to provide for a stable cell capture with as few
as a couple hundred peptide–MHC–TCR bonds. Note that the
logarithmic dependence of the critical force on both the peptide–
MHC surface concentration and the peptide–MHC–TCR afﬁnity
(which directly inﬂuences the KD
(2d)) gives rise to a wide range of Ns
and KD
(2d) values that are compatible with a stable capture.
Figure S1. Binding of OT-1 Lymphocytes to a Serial Dilution of OVA/
K
b Tetramer
The effect of tetramer dilution on cell capture was tested by
examining the binding of OT-1 lymphocytes to a serial dilution of
immobilized OVA/MHC tetramer. The cells were suspended at a
concentration of 2.5 310
6/ml and incubated on the array for 30 min
at room temperature. Following the removal of unbound cells, the
array was imaged and scored for the number of OT-1 cells on each of
the spots.
(A) A reconstruction of the relevant array region by a patchwork of
103images, revealing a monotonic reduction in the number of bound
cells with tetramer dilution. Amount of MHC tetramer deposited is
given in nanograms per spot.
(B) In this speciﬁc example, the number of immobilized OT-1
lymphocytes on the OVA/K
b spots was linearly dependent on the
amount of tetramer deposited. Averaged cell numbers and standard
errors are based on triplicate spots. The line represents a linear ﬁt to
the data.
View online at DOI: 10.1371/journal/pbio.0000065.sg001 (for Figure
S1A) (3.89 MB TIFF) and at DOI: 10.1371/jourrnal/pbio.0000065.sg002
(for Figure S1B) (5.83 MB TIFF).
Protocol S1. Online Protocol for the MHC Cellular Microarray
This protocol serves as a general template for a basic MHC cellular
microarray experiment. Depending on the exact goal of a speciﬁc
experiment, some of the parameters described may require mod-
iﬁcation.
View online at DOI: 10.1371/journal/pbio.0000065.sd001 (38 KB
DOC).
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